Dépôt DSpace/Manakin

Preoperative risk stratification in endometrial cancer using ESGO/ESTRO/ESP 2021 guidelines: accuracy with and without molecular classification

Afficher la notice abrégée

dc.rights.license CC BY eng
dc.contributor.author Bretová, P. cze
dc.contributor.author Ndukwe, M.I. cze
dc.contributor.author Laco, J. cze
dc.contributor.author Vosmiková, H. cze
dc.contributor.author Reslová, T. cze
dc.contributor.author Pohanková, D. cze
dc.contributor.author Balcarová, K. cze
dc.contributor.author Haviger, Jiří cze
dc.contributor.author Havigerová, Jana Marie cze
dc.contributor.author Sirák, I. cze
dc.date.accessioned 2025-12-05T16:08:05Z
dc.date.available 2025-12-05T16:08:05Z
dc.date.issued 2025 eng
dc.identifier.issn 1471-2407 eng
dc.identifier.uri http://hdl.handle.net/20.500.12603/2447
dc.description.abstract Background: The study aimed to evaluate the impact of integrating molecular classification with imaging-based preoperative staging on risk stratification prediction in endometrial cancer patients in accordance with ESGO/ESTRO/ESP (European Society of Gynaecological Oncology/European Society for Radiotherapy and Oncology/European Society of Pathology) 2021 guidelines. Methods: A retrospective cohort of 143 endometrial cancer patients was analyzed to assess changes in preoperative risk stratification after incorporating molecular classification into clinical evaluation. Preoperative clinical staging was primarily based on transvaginal ultrasound imaging. The overall agreement between preoperative risk group estimates (with/without molecular classification) and final postoperative outcomes was assessed using weighted Cohen’s Kappa, with bootstrap 95% confidence intervals and quadratic weights. Results: The addition of molecular classification significantly improved preoperative risk stratification accuracy (from 59.4 to 73.4%), particularly for patients post-operatively classified as high-risk. Kappa values indicated an improvement in overall agreement between preoperative and postoperative risk stratification following the addition of molecular classification, from 0.551 (95% CI: 0.430–0.671) to 0.767 (95% CI: 0.675–0.849). The non-overlapping confidence intervals indicated statistical significance. Preoperative assessment without molecular input tended to underestimate risk stratification. However, 26.6% of patients remained misclassified due to other factors, mostly within the intermediate and high-intermediate risk groups. Conclusions: Incorporating molecular classification enhances preoperative risk stratification and has the potential to tailor surgical treatment. Further validation through prospective multicentric studies is needed to support our findings. © The Author(s) 2025. eng
dc.format p. "Article number: 1302" eng
dc.language.iso eng eng
dc.publisher BioMed Central Ltd eng
dc.relation.ispartof BMC Cancer, volume 25, issue: 1 eng
dc.subject Endometrial cancer eng
dc.subject ESGO/ESTRO/ESP 2021 guidelines eng
dc.subject Molecular classification eng
dc.subject Next-generation sequencing eng
dc.subject Risk stratification eng
dc.subject Sentinel node biopsy eng
dc.subject Ultrasonography eng
dc.title Preoperative risk stratification in endometrial cancer using ESGO/ESTRO/ESP 2021 guidelines: accuracy with and without molecular classification eng
dc.type article eng
dc.identifier.obd 43882184 eng
dc.identifier.doi 10.1186/s12885-025-14741-5 eng
dc.publicationstatus postprint eng
dc.peerreviewed yes eng
dc.source.url https://bmccancer.biomedcentral.com/articles/10.1186/s12885-025-14741-5 cze
dc.relation.publisherversion https://bmccancer.biomedcentral.com/articles/10.1186/s12885-025-14741-5 eng
dc.rights.access Open Access eng


Fichier(s) constituant ce document

Ce document figure dans la(les) collection(s) suivante(s)

Afficher la notice abrégée

Chercher dans le dépôt


Parcourir

Mon compte